Hims & Hers Health, Inc. (HIMS): A Bull Case Theory

We came across a bullish thesis on Hims & Hers Health, Inc. on Investment Edge’s Substack by David Vicuña. In this article, we will summarize the bulls’ thesis on HIMS. Hims & Hers Health, Inc.'s share was trading at $28.67 as of January 28th. HIMS’s trailing and forward P/E were 56.00 and 45.05 respectively according to Yahoo Finance.

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States and internationally. HIMS’s recent launch of Labs exemplifies how the company is executing on its long-term thesis of building a deeply personalized, end-to-end healthcare platform rather than a simple telehealth or online pharmacy business.

Labs gives subscribers access to doctor-developed lab testing paired with individualized action plans that translate biological data into lifestyle guidance, focus areas, and treatments where appropriate, addressing many of the inefficiencies and frictions of traditional healthcare such as paperwork, delayed access, and generic care.

This rollout validates the investment case for Hims by testing product-market fit for what could evolve into a comprehensive, personalized health platform in the U.S., with two subscription tiers designed to broaden appeal and monetization. The opportunity is significant, as Labs extends Hims’ reach into longevity and preventive care, complementing new hormone health verticals like menopause and testosterone, while opening the door to future partnerships or acquisitions that could integrate real-time biometric data.

Fundamentally, Hims’ strength lies in its growing data-driven flywheel: more subscribers generate richer data, which improves patient outcomes, enables better offerings, drives higher revenue and cash flow, and supports reinvestment in the platform. This feedback loop underpins management’s ability to consistently expand value per customer and reinforces confidence in long-term execution under CEO Andrew Dudum.

From a market perspective, technical indicators suggest improving momentum, with key resistance around $40 serving as an important near-term test, while longer-term investors may view current levels as attractive accumulation points given the strengthening fundamentals. Overall, Labs reinforces the view of Hims as a health “super app” in the making, leveraging data science, software, and medical expertise to disrupt a broken healthcare system and position the company for sustained growth and value creation.

Previously, we covered a bullish thesis on Hims & Hers Health, Inc. (HIMS) by Oliver | MMMT Wealth in May 2025, which highlighted the company’s breakout financial performance, accelerating revenue growth, expanding free cash flow, and rising personalization-driven monetization. HIMS’s stock price has depreciated by approximately 45.23% since our coverage. David Vicuña shares a similar view but emphasizes on the strategic importance of Labs in building a personalized health platform.

Hims & Hers Health, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 35 hedge fund portfolios held HIMS at the end of the third quarter which was 34 in the previous quarter. While we acknowledge the risk and potential of HIMS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than HIMS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.